nebusiness.co.uk - Tag - astrazeneca

AstraZeneca chief stripped of his shares

nebusiness.co.uk — Tue, 17 Jul 2012 07:03:00 GMT

THE former boss of pharmaceuticals giant AstraZeneca has waived his entitlement to a 2012 annual bonus and has been denied performance-related share awards for the last two years, it emerged yesterday.

Pharmaceutical boss's £40m payout under fire

nebusiness.co.uk — Mon, 30 Apr 2012 07:03:00 GMT

THE departing boss of AstraZeneca will reportedly enjoy a "golden goodbye" worth up to £40m, despite leaving the pharmaceuticals giant with concerns over the development of new drugs.

AstraZeneca to axe jobs

nebusiness.co.uk — Thu, 02 Feb 2012 07:44:00 GMT

Pharmaceuticals giant AstraZeneca said today that it will axe 7,300 jobs by the end of 2014 as part of a fresh round of cost savings.

Drug test setbacks are a blow to AstraZeneca

nebusiness.co.uk — Wed, 21 Dec 2011 08:00:00 GMT

DRUGS giant AstraZeneca has warned profits would be at the lower end of its expectations after suffering setbacks in its efforts to produce new blockbuster treatments.

Drugs firm AstraZeneca posts very healthy profit

nebusiness.co.uk — Fri, 28 Jan 2011 08:00:00 GMT

ASTRAZENECA has posted better-than-expected profits as key brands such as cholesterol product Crestor helped it weather testing conditions.

Delay on drug approval sees AstraZeneca shares drop

nebusiness.co.uk — Sat, 18 Dec 2010 00:28:00 GMT

PHARMACEUTICALS giant AstraZeneca saw shares tumble yesterday after approval for a new heart drug was delayed by a US regulator’s demand for more information.

Drug company shares rocket

nebusiness.co.uk — Thu, 01 Jul 2010 07:09:00 GMT

PHARMACEUTICALS giant AstraZeneca saw its shares rocket yesterday after it won a three-year battle over its Crestor cholesterol drug which will keep rivals at bay in the US until 2016.

Snap up a bargain with Debenhams

nebusiness.co.uk — Mon, 30 Nov 2009 00:00:00 GMT

DEBENHAMS – We have upgraded our recommendation on Debenhams to buy. The retailer, which has 144 stores and £2.3bn in revenue, has some of the cheapest stock in our coverage, with a 10.2x 1-year forward P/E on our 8p estimate.

Revenue expectations fail to excite

nebusiness.co.uk — Mon, 16 Feb 2009 08:23:00 GMT

ASTRAZENECA: AstraZeneca recently reported its Q4 and FY2008 results. Despite 2008 EPS coming in ahead of our expectations, driven by exchange rate movements, the market was a little disappointed by its guidance for 2009.